489 related articles for article (PubMed ID: 9529307)
1. Pentavalent technetium-99m-dimercaptosuccinic acid scintigraphy in renal osteodystrophy.
Higuchi T; Hirano T; Inoue T; Aoki J; Ueki K; Wakamatsu R; Yano S; Naruse T; Endo K
J Nucl Med; 1998 Mar; 39(3):541-3. PubMed ID: 9529307
[TBL] [Abstract][Full Text] [Related]
2. 99mTc(V)-DMSA scintigraphy in monitoring the response of bone disease to vitamin D3 therapy in renal osteodystrophy.
Sarikaya A; Sen S; Hacimahmutoglu S; Pekindil G
Ann Nucl Med; 2002 Feb; 16(1):19-23. PubMed ID: 11922204
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies with pentavalent technetium-99m dimercaptosuccinic acid.
Lam AS; Puncher MR; Blower PJ
Eur J Nucl Med; 1996 Dec; 23(12):1575-82. PubMed ID: 8929310
[TBL] [Abstract][Full Text] [Related]
4. Intraosseous hemangiomatosis: technetium-99m(V)dimercaptosuccinic acid and technetium-99m-hydroxymethylene diphosphonate imaging.
Kobayashi H; Shigeno C; Sakahara H; Hosono M; Hosono M; Yao ZS; Endo K; Konishi J
J Nucl Med; 1994 Sep; 35(9):1482-4. PubMed ID: 8071696
[TBL] [Abstract][Full Text] [Related]
5. Pentavalent technetium-99m DMSA uptake in pseudofractures of osteomalacia.
Sahin M; Basoglu T; Albayrak S; Canbaz F; Yapici O
Clin Nucl Med; 2001 Jan; 26(1):62-4. PubMed ID: 11139060
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of Tc-99m (V) DMSA for chondrogenic tumors with positive Tc-99m HMDP uptake on bone scintigraphy.
Kobayashi H; Kotoura Y; Hosono M; Sakahara H; Hosono M; Yao ZS; Tsuboyama T; Yamamuro T; Endo K; Konishi J
Clin Nucl Med; 1995 Apr; 20(4):361-4. PubMed ID: 7788996
[TBL] [Abstract][Full Text] [Related]
7. [Bone scintigraphy in evaluation of the effect of renal transplantation in patients with renal osteodystrophy].
Seto K
Rinsho Hoshasen; 1989 Nov; 34(12):1433-6. PubMed ID: 2593286
[TBL] [Abstract][Full Text] [Related]
8. Increased bone marrow uptake on Tc-99m DMSA scintigraphy in a patient with renal osteodystrophy.
Caglar M; Naldöken S
Ann Nucl Med; 1993 Nov; 7(4):281-3. PubMed ID: 8292457
[TBL] [Abstract][Full Text] [Related]
9. The role of Tc-99m (V) DMSA scintigraphy in the evaluation of superscan on bone scintigraphy.
Yüksel D; Ilgan S; Arslan N; Uğur O; Oztürk E; Bayhan H
Clin Nucl Med; 2000 Mar; 25(3):193-6. PubMed ID: 10698416
[TBL] [Abstract][Full Text] [Related]
10. The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions.
Ergün EL; Kara PO; Gedik GK; Kars A; Türker A; Caner B
Ann Nucl Med; 2007 Jul; 21(5):275-83. PubMed ID: 17634845
[TBL] [Abstract][Full Text] [Related]
11. Tc-99m pentavalent DMSA scintigraphy in myelofibrosis detection.
Koutsikos JT; Velidaki A; Athanasoulis T
Clin Nucl Med; 2006 Dec; 31(12):806-7. PubMed ID: 17117079
[TBL] [Abstract][Full Text] [Related]
12. A trial of semiquantitative analysis of whole body bone scintigraphy in renal osteodystrophy.
Kida T; Narita S
Eur J Nucl Med; 1987; 13(1):36-40. PubMed ID: 3109916
[TBL] [Abstract][Full Text] [Related]
13. Analogy between tumor uptake of technetium(V)-99m dimercaptosuccinic acid (DMSA) and technetium-99m-MDP.
Wulfrank DA; Schelstraete KH; Small F; Fallais CJ
Clin Nucl Med; 1989 Aug; 14(8):588-93. PubMed ID: 2553315
[TBL] [Abstract][Full Text] [Related]
14. Bone metastases demonstrated by pentavalent Tc-99m DMSA and Tc-99m HMDP.
Hirano T; Otake H
Clin Nucl Med; 1997 Sep; 22(9):640-1. PubMed ID: 9298304
[No Abstract] [Full Text] [Related]
15. Evaluation of metastatic bone disease with pentavalent 99Tc(m)-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions.
Sahin M; Basoglu T; Bernay I; Yapici O; Canbaz F; Yalin T
Nucl Med Commun; 2000 Mar; 21(3):251-8. PubMed ID: 10823327
[TBL] [Abstract][Full Text] [Related]
16. The role of 99mTc(V)-DMSA scan as compared to 99mTc-MDP and CT scans in imaging the primary tumor and metastases of osteosarcoma.
Zissimopoulos A; Zanglis A; Andreopoulos D; Baziotis N
Hell J Nucl Med; 2005; 8(3):162-4. PubMed ID: 16390022
[TBL] [Abstract][Full Text] [Related]
17. Pentavalent technetium-99m-DMSA uptake in a patient having multiple myeloma without amyloidosis.
Ohnishi T; Noguchi S; Murakami N; Tajiri J; Morita M; Tamaru M; Hoshi H; Watanabe K
J Nucl Med; 1991 Sep; 32(9):1785-7. PubMed ID: 1652629
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-(V) DMSA uptake in systemic AL amyloidosis and normal bone scintigraphy.
Sonmez B; Cekic AB; Erkut N; Piskin B; Sonmez M
Hell J Nucl Med; 2010; 13(1):69-70. PubMed ID: 20411178
[No Abstract] [Full Text] [Related]
19. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
Colao A; Ferone D; Lombardi G; Lastoria S
Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of 99mTc-methylene diphosphonate and 99mTc-pentavalent DMSA compared with 99mTc-sestamibi for palpable breast lesions.
Massardo T; Alonso O; Kabasakal L; Llamas-Olier A; Shankar UR; Zhu H; Delgado L; González P; Mut F; Padhy AK
J Nucl Med; 2002 Jul; 43(7):882-8. PubMed ID: 12097457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
